Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma : A Nationwide Population-Based Study (THNS-2021-08)
© 2024. The Author(s)..
BACKGROUND: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs.
OBJECTIVE: We conducted a multicenter, retrospective study to evaluate the role of cetuximab TBP in patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy.
PATIENTS AND METHODS: Patients with R/M HNSCC who had tumor progression after first-line cetuximab-containing chemotherapy were included into our study. Oncologic outcomes were estimated including time to cetuximab treatment discontinuation (TTD), progression-free survival 2 (PFS2), overall survival (OS), overall response rate (ORR), and disease control rate (DCR). Multivariate cox regression analysis with survival were conducted. Subgroup analysis with P16 and programmed death ligand 1 expression were performed.
RESULTS: A total of 498 patients were eligible with 259 patients in the TBP group and 239 patients in the non-TBP group. The most common first-line chemotherapy was the EXTREME regimen in both groups. As for second-line treatment, the most common regimen were TPEx in the TBP group and taxane-based chemotherapy in the non-TBP group. Median TTD was 8.7 months in TBP and 5.5 months in non-TBP (p < 0.001). In terms of survival, median OS1 was significant longer in the TBP group than in the non-TBP group [14.1 months versus 10.9 months (p = 0.016)]. Multivariate analysis demonstrated cetuximab TBP was a factor independently associated with OS.
CONCLUSIONS: Our retrospective study suggests cetuximab TBP to be effective and to provide better survival for patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Further prospective studies are warranted to validate the role of cetuximab TBP in R/M HNSCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Targeted oncology - 19(2024), 1 vom: 29. Jan., Seite 51-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Hung-Ming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 01.02.2024 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11523-023-01028-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367754762 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367754762 | ||
| 003 | DE-627 | ||
| 005 | 20240320234036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11523-023-01028-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM367754762 | ||
| 035 | |a (NLM)38285067 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Hung-Ming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |b A Nationwide Population-Based Study (THNS-2021-08) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2024 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Little is known regarding the association of cetuximab treatment beyond progression (TBP) with survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Although immune checkpoint inhibitors (ICIs) are now considered as first-line treatment, not all patients are suitable for ICIs | ||
| 520 | |a OBJECTIVE: We conducted a multicenter, retrospective study to evaluate the role of cetuximab TBP in patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy | ||
| 520 | |a PATIENTS AND METHODS: Patients with R/M HNSCC who had tumor progression after first-line cetuximab-containing chemotherapy were included into our study. Oncologic outcomes were estimated including time to cetuximab treatment discontinuation (TTD), progression-free survival 2 (PFS2), overall survival (OS), overall response rate (ORR), and disease control rate (DCR). Multivariate cox regression analysis with survival were conducted. Subgroup analysis with P16 and programmed death ligand 1 expression were performed | ||
| 520 | |a RESULTS: A total of 498 patients were eligible with 259 patients in the TBP group and 239 patients in the non-TBP group. The most common first-line chemotherapy was the EXTREME regimen in both groups. As for second-line treatment, the most common regimen were TPEx in the TBP group and taxane-based chemotherapy in the non-TBP group. Median TTD was 8.7 months in TBP and 5.5 months in non-TBP (p < 0.001). In terms of survival, median OS1 was significant longer in the TBP group than in the non-TBP group [14.1 months versus 10.9 months (p = 0.016)]. Multivariate analysis demonstrated cetuximab TBP was a factor independently associated with OS | ||
| 520 | |a CONCLUSIONS: Our retrospective study suggests cetuximab TBP to be effective and to provide better survival for patients with R/M HNSCC after failure of first-line cetuximab-containing chemotherapy. Further prospective studies are warranted to validate the role of cetuximab TBP in R/M HNSCC | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 700 | 1 | |a Lou, Pei-Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Muh-Hwa |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tein-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Lien, Ming-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jin-Ching |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jo-Pai |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Wei-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Hsueh-Ju |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Tai-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Yen, Chia-Jui |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shang-Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hui-Ching |e verfasserin |4 aut | |
| 700 | 1 | |a Hsieh, Meng-Che |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Targeted oncology |d 2009 |g 19(2024), 1 vom: 29. Jan., Seite 51-58 |w (DE-627)NLM187616825 |x 1776-260X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:1 |g day:29 |g month:01 |g pages:51-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11523-023-01028-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 1 |b 29 |c 01 |h 51-58 | ||